CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah

“While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point.”

Read more

CSRxP Calls for Action on CREATES Act

CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing released this statement from spokesman Will Holley on today’s House Judiciary Subcommittee on […]

Read more

Avik Roy Unveils “The Competition Prescription”

Read “The Competition Prescription,” a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down.

Read more

CSRxP Applauds Introduction of the CREATES Act

“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.”

Read more